Myriad Genetics, Inc. (MYGN) Financial Statements
Myriad Genetics, Inc. (MYGN) reported trailing twelve-month revenue of $806.6M (down 3.2% year on year) and net income of -$112.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$7.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MYGNMyriad Genetics, Inc.Follow MYGN — free
—
Price chart with a free account
- Market cap
- 556.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Jun 11 | FY2012 Jun 12 | FY2013 Jun 13 | FY2014 Jun 14 | FY2015 Jun 15 | FY2016 Jun 16 | FY2017 Jun 17 | FY2018 Jun 18 | FY2019 Jun 19 | FY2020 Jun 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.40 | 0.50 | 0.61 | 0.78 | 0.72 | 0.75 | 0.77 | 0.74 | 0.85 | 0.64 | 0.69 | 0.68 | 0.75 | 0.84 | 0.82 | 0.81 | |
| Gross profit | 0.36 | 0.44 | 0.55 | 0.68 | 0.59 | 0.62 | 0.63 | — | — | — | — | — | 0.52 | 0.59 | 0.58 | 0.56 | |
| Research & development | 0.03 | 0.04 | 0.05 | 0.07 | 0.08 | 0.07 | 0.07 | 0.07 | 0.09 | 0.08 | 0.08 | 0.09 | 0.09 | 0.11 | 0.11 | 0.11 | |
| Operating income | 0.16 | 0.18 | 0.23 | 0.27 | 0.13 | 0.15 | 0.04 | 0.12 | 0.01 | -0.23 | -0.19 | -0.14 | -0.26 | -0.12 | -0.39 | -0.10 | |
| Pre-tax income | 0.16 | 0.18 | 0.23 | 0.28 | 0.13 | 0.16 | 0.04 | 0.12 | 0.00 | -0.22 | -0.06 | -0.14 | -0.26 | -0.12 | -0.40 | -0.11 | |
| Income tax | 0.06 | 0.07 | 0.09 | 0.10 | 0.05 | 0.04 | 0.02 | -0.01 | -0.00 | -0.02 | -0.03 | -0.03 | 0.00 | 0.00 | -0.03 | 0.00 | |
| Net income | 0.10 | 0.11 | 0.15 | 0.18 | 0.08 | 0.12 | 0.02 | 0.13 | 0.00 | -0.20 | -0.03 | -0.11 | -0.26 | -0.13 | -0.37 | -0.11 | |
| Diluted EPS ($) | 1.10 | 1.30 | 1.77 | 2.25 | 1.07 | 1.60 | 0.25 | 1.85 | 0.06 | -2.69 | -0.35 | -1.39 | -3.18 | -1.41 | -3.95 | -1.18 | |
| Diluted shares (bn) | 0.092 | 0.086 | 0.083 | 0.078 | 0.074 | 0.073 | 0.069 | 0.072 | 0.076 | 0.074 | 0.078 | 0.081 | 0.083 | 0.091 | 0.093 | — |
USD billions · SEC XBRL
Myriad Genetics, Inc. — questions
- What is Myriad Genetics, Inc.'s revenue?
- $806.6M over the twelve months to 2026-06-30, down 3.2% year on year, from its 10-Q and 10-K filings.
- What is Myriad Genetics, Inc.'s net income?
- -$112.6M over the twelve months to 2026-06-30.
- What is Myriad Genetics, Inc.'s free cash flow?
- -$7.3M over the twelve months to 2026-06-30.
- What are Myriad Genetics, Inc.'s diluted earnings per share?
- $-1.18 over the twelve months to 2026-06-30.
Every figure on this page comes from Myriad Genetics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.